TABLE 1.
Characteristics of 173 female subjects
|
n = 173 n (%) |
|
|---|---|
| Median age at breast cancer diagnosis: years (range) | 45 (21–79) |
| Median age at genetic mutation testing: years (range) | 46 (21–79) |
| Timing of genetic testing relative to breast cancer diagnosis and surgery | |
| Genetic testing before breast cancer diagnosis | 15 (8.7) |
| Genetic testing after diagnosis but before surgery | 56 (32.4) |
| Genetic testing after surgery | 102 (59.0) |
| Laterality | |
| Bilateral breast cancer | 13 (7.5) |
| Unilateral breast cancer | 160 (92.5) |
| Clinical TNM stage | |
| 0 | 10 (7.3) |
| 1 | 49 (35.8) |
| 2 | 53 (38.7) |
| 3 | 22 (16.1) |
| 4 | 3 (2.2) |
| Unknown | 36 |
| Nodal status | |
| Negative | 98 (59.4) |
| Positive | 67 (40.6) |
| Unknown | 8 |
| Estrogen receptor status | |
| Positive | 86 (54.1) |
| Negative | 73 (45.9) |
| Unknown | 14 |
| HER2 status | |
| Positive | 10 (7.8) |
| Negative | 118 (92.2) |
| Unknown or not applicable | 45 |
| Initial breast surgery | |
| Lumpectomy | 60 (34.7) |
| Unilateral mastectomy | 21 (12.1) |
| Bilateral mastectomy | 88 (50.9) |
| Nonea | 4 (2.3) |
| Neoadjuvant systemic therapy | |
| None | 121 (72.9) |
| Neoadjuvant chemotherapy | 45 (27.1) |
| Neoadjuvant endocrine therapy | 0 (0.0) |
| Unknown | 7 |
| Adjuvant chemotherapy | |
| Yes | 90 (54.6) |
| No | 75 (45.5) |
| Unknown | 8 |
| Adjuvant radiation therapy | |
| Yes | 75 (45.5) |
| No | 90 (54.6) |
| Unknown | 8 |
TNM tumor-node metastasis, HER human epidermal growth factor receptor
a
This included three stage 4 patients who at presentation underwent no primary breast surgery and one patient with no breast primary tumor who underwent axillary lymph node dissection only as initial surgery